Freeline Therapeutics Holdings PLC expected to post a loss of 68  cents a share - Earnings Preview

Freeline Therapeutics Holdings

29/03/2022 12:01

* Freeline Therapeutics Holdings PLC  FRLN.OQ   FRLN.O  is
expected to show no change in quarterly revenue when it reports 
results on March 31. 
    * ​Refinitiv's mean analyst estimate for Freeline
Therapeutics
Holdings PLC is for a loss of 68 cents per share. For the same
quarter last year, the company reported a loss of 88 cents per
share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Freeline
Therapeutics Holdings PLC is $10​, above​ its last closing price
of $1.17. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -1.02       -1.01      -0.86     Beat    15.1
 Jun. 30 2021  -0.97       -0.97      -1.12     Missed  -15.7
 Mar. 31 2021  -0.77       -0.78      -0.98     Missed  -25.2​
 Dec. 31 2020              -0.70      -0.88     Missed  -24.8
 ​​Sep.                    -0.72                        
 30 2020                                                
                                                        ​
 This summary was machine generated March 29 at 11:01 GMT.  All
figures in US dollars  unless otherwise stated